Molecular testing for personalized cancer therapy at MD Anderson
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
M.D. Anderson Cancer Center · NCT01772771
This study is testing if looking at the genetic makeup of tumors in cancer patients can help find the best personalized treatments and match them with suitable clinical trials.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 12000 (estimated) |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT01772771 on ClinicalTrials.gov |
What this trial studies
This observational study conducts standardized testing of tumor tissue samples to identify genetic mutations in patients with various types of cancer, including glioma, melanoma, and sarcoma. The primary goal is to assist in personalized cancer therapy by establishing a database of mutations and alterations in cancer-related genes. Researchers aim to determine the frequency of these mutations and their impact on treatment responses, ultimately helping to match patients with relevant clinical trials. The study also explores the feasibility of identifying actionable targets for targeted therapy based on genetic profiling.
Who should consider this trial
Good fit: Ideal candidates include patients with documented cancer types such as glioma, sarcoma, melanoma, or hematologic malignancies who are willing to undergo genetic testing.
Not a fit: Patients with benign tumors or those who do not have sufficient archived tissue for testing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatment options for cancer patients based on their unique genetic profiles.
How similar studies have performed: Other studies utilizing molecular profiling for personalized cancer therapy have shown promise, indicating a growing body of evidence supporting this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have histologically, radiographic, or cytologically documented cancer, suspected glioma, sarcoma, melanoma or hematologic cancer. Patients with benign tumors may also be consented at the discretion of the attending physician if molecular profiling is felt to have potential clinical implications. * Patients must have the ability to understand and the willingness to sign a written informed consent document * Patients may be consented without confirming the amount and quality of archival diagnostic or residual tissue available. However, research testing will only be performed on patients who have sufficient archived diagnostic tissue or residual tissue banked in one of the authorized tissue banks at MD Anderson available to proceed with testing. The extent of testing may be modified based on amount of tissue available. If any new tissue acquisition including a biopsy and/or surgical resection etc. is being ordered for clinical care or another research study, or an operation is being performed testing can be ordered on that sample * Circulating cell-free deoxyribonucleic acid (cfDNA) Cohort: Circulating cell-free DNA next generation sequencing (NGS) testing will be performed with the Clinical Laboratory Improvement Act (CLIA)-certified Guardant360 panel (or equivalent) for select patients. This particular cohort of research collaboration will be supported by Guardant Health, Inc. at no charge to MD Anderson. Patients who are being considered for enrollment into clinical trials in the next 2 lines of therapy may be enrolled. Selected patients may have cfDNA, circulating RNA /exosome/circulating tumor cell testing approaches performed on alternate platforms (eg Foundation ACT)
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Funda Meric-Bernstam — M.D. Anderson Cancer Center
- Study coordinator: Funda Meric-Bernstam, MD
- Email: fmeric@mdanderson.org
- Phone: 713-792-6940
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Melanoma, Sarcoma